News

FDA Offers New Resource on Biosimilars for Health Care Providers (copy 1)


 

References

A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.

In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.

The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.

Recommended Reading

NIH Launches Online Application Portal for Undiagnosed Diseases Network
MDedge Dermatology
Patient Organizations May Apply to Join Natural History Study Project
MDedge Dermatology
Rare Disease Community Prepares for Worldwide Observance of Rare Disease Day
MDedge Dermatology
Omnibus Spending Bill Includes Provisions Important to the Rare Disease Community
MDedge Dermatology
FDA Invites Patient Organizations to Organize Public Meetings to Enhance Awareness of Their Needs
MDedge Dermatology
NIH Releases Its Strategic Plan
MDedge Dermatology
EADV: DLX105 is a novel treatment strategy for Behçet’s flares
MDedge Dermatology
A Case of Bloom Syndrome With Uncommon Clinical Manifestations Confirmed on Genetic Testing
MDedge Dermatology
Elevated cardiovascular risks linked to hidradenitis suppurativa
MDedge Dermatology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Dermatology